More good news for AstraZeneca's Crestor: Managed care pharmacy directors are saying they'll pay for the statin for healthy patients without high LDL cholesterol, but with elevated high sensitivity C-reactive protein, after the Jupiter trial found outcomes benefits from Crestor use in those patients. Release